Kinomica utilizes phosphoproteomics through its KScan® diagnostic platform to enhance cancer treatment selection by identifying the most effective therapies for individual patients. This approach provides critical insights into protein activation and signaling pathways, enabling the development of targeted therapies and improved patient outcomes.
Funding
$13.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BGFounders
Product
Problem
Selecting the most effective cancer therapies for individual patients is challenging due to the complex and variable nature of the disease. Current diagnostic methods often fail to provide sufficient insight into protein activation and signaling pathways, hindering the development of targeted therapies and optimal treatment decisions.
Solution
Kinomica's KScan® platform utilizes phosphoproteomics to enhance cancer treatment selection by identifying therapies most likely to benefit individual patients. By analyzing protein phosphorylation, KScan® provides critical insights into the activation status of proteins and signaling pathways within cancer cells. This information enables clinicians to better understand the unique characteristics of a patient's tumor and select therapies that specifically target the dysregulated pathways driving its growth. The platform aims to improve patient outcomes by guiding the selection of targeted therapies and identifying potential drug candidates for further development.
Target Audience
The primary target audience includes oncologists, pathologists, and pharmaceutical companies involved in cancer research and treatment.
Features
- Phosphoproteomic analysis of patient samples to identify activated signaling pathways.
- KScan® diagnostic platform for comprehensive assessment of protein phosphorylation.
- Identification of potential drug targets based on phosphoproteomic profiles.
- Prediction of patient response to specific therapies based on pathway activation.